{"id":728763,"date":"2023-02-06T06:53:08","date_gmt":"2023-02-06T11:53:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/"},"modified":"2023-02-06T06:53:08","modified_gmt":"2023-02-06T11:53:08","slug":"novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/","title":{"rendered":"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC<sup>\u00ae<\/sup> Shows on February 7<\/b><\/p>\n<p class=\"bwalignc\"><i>Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on \u201cIt Takes Two with Mary &amp; Sandra\u201d at 2 p.m. ET and \u201cGirl\u2019s Night In With Courtney &amp; Jane\u201d at 9 p.m. ET<\/i><\/p>\n<p>EMERYVILLE, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.novabay.com%2F&amp;esheet=53299902&amp;newsitemid=20230206005067&amp;lan=en-US&amp;anchor=NovaBay%26%23174%3B+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=244f28d0ed39f0df2a1529f3713c7047\">NovaBay<sup>\u00ae<\/sup> Pharmaceuticals, Inc<\/a>. (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be discussing DERMAdoctor<sup>\u00ae<\/sup>\u2019s problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on \u201cIt Takes Two With Mary &amp; Sandra\u201d at 2 p.m. Eastern time and on \u201cGirl\u2019s Night In With Courtney &amp; Jane\u201d at 9 p.m. Eastern time.\n<\/p>\n<p>\n\u201cThis is the ideal time of year for our moisturizing Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm as eczema flare-ups occur more frequently in the winter months due to cold weather and dry air from indoor heating systems,\u201d said Dr. Kunin. \u201cOur clinical-strength, high-potency balm helps to temporarily relieve eczema, rashes, redness, dryness and itchiness and is suitable for the whole family wherever eczema strikes. Our product packaging proudly features the National Eczema Association Seal of Acceptance\u2122 for meeting the Association\u2019s rigorous standard for providing benefits and improving the quality of life for people with eczema and sensitive skin.\n<\/p>\n<p>\n\u201cIt\u2019s exciting to appear on these two popular QVC shows to spotlight the significant benefits of Calm Cool + Corrected Eczema Clinical Repair Balm,\u201d added Dr. Kunin. \u201cQVC attracts a demographic that complements our social media promotions to reach the estimated 31 million Americans with eczema who may benefit from our product.\u201d\n<\/p>\n<p>\nCalm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm features eczema-active 1% colloidal oatmeal with enhanced beta glucan to help relieve minor skin irritations and itching, together with an advanced complex of ceramides and essential lipids to maximize hydration and dermatologic botanicals that calm and soothe the skin.\n<\/p>\n<p>\nDr. Kunin is a board-certified dermatologist, author, clinician, educator, television personality and recognized trailblazer in the skincare industry. She founded DERMAdoctor to formulate and commercialize highly effective, prestige solutions for common skincare concerns that have been overlooked by the beauty industry. DERMAdoctor delivers on the promise that clinical skin therapy can be simple and easy to use, while providing significant and measurable results. DERMAdoctor products are developed to provide real solutions for real people with real skin-related concerns.\n<\/p>\n<p><b>About NovaBay Pharmaceuticals, Inc.<\/b><\/p>\n<p>\nNovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay\u2019s leading product, Avenova<sup>\u00ae<\/sup> Antimicrobial Lid &amp; Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor<sup>\u00ae<\/sup> offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne<sup>\u00ae<\/sup> brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase<sup>\u00ae<\/sup> brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.\n<\/p>\n<p><b>NovaBay Pharmaceuticals Forward-Looking Statements<\/b><\/p>\n<p>\nExcept for historical information herein, matters set forth in this press release may be forward looking within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management\u2019s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company\u2019s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company\u2019s products will not be as large as expected, the Company\u2019s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company\u2019s cash needs. Other risks relating to NovaBay\u2019s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay\u2019s latest Form 10-Q\/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading \u201cRisk Factors.\u201d The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.\n<\/p>\n<p><b><span class=\"bwuline\">Socialize and Stay Informed on NovaBay<\/span><\/b><span class=\"bwuline\">\u2019<\/span><b><span class=\"bwuline\">s Progress<br \/>\n<br \/><\/span><\/b>Like us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fnovabaypharma%2F&amp;esheet=53299902&amp;newsitemid=20230206005067&amp;lan=en-US&amp;anchor=Facebook&amp;index=2&amp;md5=842403b396a58b20a9353cd948ab23fd\">Facebook<br \/>\n<\/a><br \/>Follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FNovaBayPharma&amp;esheet=53299902&amp;newsitemid=20230206005067&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=095ec03747d093f16c6ebdcd1863185c\">Twitter<br \/>\n<\/a><br \/>Connect with NovaBay on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnovabay-pharmaceuticals%2F&amp;esheet=53299902&amp;newsitemid=20230206005067&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=8b083375c9d6ce80908db6f3f6ee739d\">LinkedIn<br \/>\n<\/a><br \/>Visit NovaBay\u2019s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnovabay.com%2F&amp;esheet=53299902&amp;newsitemid=20230206005067&amp;lan=en-US&amp;anchor=Website&amp;index=5&amp;md5=0f2d20036a15a95193f8206dc23e7b34\">Website<\/a><\/p>\n<p><b><span class=\"bwuline\">Avenova Purchasing Information<br \/>\n<br \/><\/span><\/b>For NovaBay Avenova purchasing information:<br \/>\n<br \/>Please call 800-890-0329 or email <a rel=\"nofollow\" href=\"mailto:sales@avenova.com\">sales@avenova.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avenova.com&amp;esheet=53299902&amp;newsitemid=20230206005067&amp;lan=en-US&amp;anchor=Avenova.com&amp;index=6&amp;md5=a74ee0a837ebe282863f74576f552bd2\">Avenova.com<\/a><\/p>\n<p><b><span class=\"bwuline\">DERMAdoctor Purchasing Information<br \/>\n<br \/><\/span><\/b>For DERMAdoctor purchasing information:<br \/>\n<br \/>Please call 877-337-6237 or email <a rel=\"nofollow\" href=\"mailto:service@dermadoctor.com\">service@dermadoctor.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dermadoctor.com%2F&amp;esheet=53299902&amp;newsitemid=20230206005067&amp;lan=en-US&amp;anchor=DERMAdoctor.com&amp;index=7&amp;md5=e1e9613da0046550e179e56fea7b9b3e\">DERMAdoctor.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230206005067\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230206005067\/en\/<\/a><\/span><\/p>\n<p><b><span class=\"bwuline\">NovaBay Contact<br \/>\n<\/span><\/b><br \/>Justin Hall<br \/>\n<br \/>Chief Executive Officer and General Counsel<br \/>\n<br \/>510-899-8800<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jhall@novabay.com\">jhall@novabay.com<\/a><\/p>\n<p><b><span class=\"bwuline\">Investor Contact<br \/>\n<\/span><\/b><br \/>LHA Investor Relations<br \/>\n<br \/>Jody Cain<br \/>\n<br \/>310-691-7100<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jcain@lhai.com\">jcain@lhai.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Women Biotechnology Pharmaceutical Optical Health Consumer Cosmetics Retail<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230206005067\/en\/841167\/3\/nby_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on \u201cIt Takes Two with Mary &amp; Sandra\u201d at 2 p.m. ET and \u201cGirl\u2019s Night In With Courtney &amp; Jane\u201d at 9 p.m. ET EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be discussing DERMAdoctor\u00ae\u2019s problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on \u201cIt Takes Two With Mary &amp; Sandra\u201d at 2 p.m. Eastern &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728763","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on \u201cIt Takes Two with Mary &amp; Sandra\u201d at 2 p.m. ET and \u201cGirl\u2019s Night In With Courtney &amp; Jane\u201d at 9 p.m. ET EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be discussing DERMAdoctor\u00ae\u2019s problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on \u201cIt Takes Two With Mary &amp; Sandra\u201d at 2 p.m. Eastern &hellip; Continue reading &quot;NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-06T11:53:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7\",\"datePublished\":\"2023-02-06T11:53:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/\"},\"wordCount\":981,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/\",\"name\":\"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-02-06T11:53:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/","og_locale":"en_US","og_type":"article","og_title":"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 - Market Newsdesk","og_description":"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on \u201cIt Takes Two with Mary &amp; Sandra\u201d at 2 p.m. ET and \u201cGirl\u2019s Night In With Courtney &amp; Jane\u201d at 9 p.m. ET EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be discussing DERMAdoctor\u00ae\u2019s problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on \u201cIt Takes Two With Mary &amp; Sandra\u201d at 2 p.m. Eastern &hellip; Continue reading \"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-06T11:53:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7","datePublished":"2023-02-06T11:53:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/"},"wordCount":981,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/","name":"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-02-06T11:53:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230206005067r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-chief-product-officer-dr-audrey-kunin-to-discuss-dermadoctors-eczema-treatment-on-two-qvc-shows-on-february-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor\u2019s Eczema Treatment on Two QVC\u00ae Shows on February 7"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728763"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728763\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}